A multicenter experience using adipose-derived mesenchymal stem cell therapy for cats with chronic, non-responsive gingivostomatitis

Boaz Arzi, Santiago Peralta, Nadine Fiani, Natalia Vapniarsky, Nopmanee Taechangam, Ubaldo Delatorre, Kaitlin C. Clark, Naomi J. Walker, Megan R. Loscar, Milinda J. Lommer, Amy Fulton, Jean Battig, Dori L. Borjesson

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: The ability of mesenchymal stem cells (MSCs) to modulate immune responses inspired a series of clinical trials addressing oral mucosal inflammation. We previously reported on the safety and efficacy of fresh, allogeneic and autologous, adipose-derived mesenchymal stem cells (ASCs) to treat feline gingivostomatitis (FCGS), an oral mucosal inflammatory disease that shares similarities with human oral lichen planus. Methods: To meet clinical demand and goals for future commercialization, we determined the feasibility of shipping fresh ASCs to distant clinics and extended our pilot studies to expand safety and efficacy data for shipped and non-shipped ASCs in a cohort of 18 FCGS cats enrolled locally and at a few different locations within the USA. Results: We found that ASCs retained their viability, phenotype, and function after shipment. ASCs administered systemically resulted in a 72% positive response rate, identical to that noted in our previous studies. Cats that responded to ASC therapy had a significant decrease in circulating globulin concentration and histological evidence of decreased CD3+ T cells and CD20+ B cells in the oral mucosa. Responder cats also had significantly decreased percentages of CD8lo cells in blood prior to and at 3 months post-ASC therapy. CD8lo cells may serve as a potential "predictor" for response to systemic ASC therapy. Conclusion: Fresh feline ASCs can be successfully shipped and administered to cats with FCGS. ASCs modulate the immune response and demonstrate efficacy for chronic oral mucosal inflammatory lesions that are characterized by CD8+ T cell inflammation and T cell activation. FCGS is a potentially useful naturally occurring large animal model of human oral inflammatory diseases.

Original languageEnglish (US)
Article number115
JournalStem Cell Research and Therapy
Volume11
Issue number1
DOIs
StatePublished - Mar 13 2020

Keywords

  • Allogeneic
  • Autologous
  • Cats
  • Fresh
  • Gingivostomatitis
  • Immunomodulation
  • Multicenter
  • Oral mucosa
  • Shipped adipose-derived stem cells

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology

Fingerprint Dive into the research topics of 'A multicenter experience using adipose-derived mesenchymal stem cell therapy for cats with chronic, non-responsive gingivostomatitis'. Together they form a unique fingerprint.

  • Cite this